# MicroRNAs in circulating extracellular vesicles as biomarkers of early colorectal cancer captured using high mannose N-glycan-specific lectin from Oscillatoria Agardhii

**Authors:** Sanae Nakayama, Miyabi Umeda, Kenya Kobayashi, Yukiko Nakano, Kanji Hori, Tsukuru Umemura, Hiroshi Kurokawa

PMC · DOI: 10.3389/fonc.2025.1619460 · 2025-07-30

## TL;DR

A new method using a cyanobacterium-derived lectin captures extracellular vesicles in blood, revealing microRNA biomarkers for early colorectal cancer detection.

## Contribution

Demonstrates that OAA1-captured EVs contain miRNAs with high accuracy in distinguishing early-stage CRC from healthy individuals.

## Key findings

- OAA1 effectively captures HM N-glycans and EVs from plasma samples.
- Five miRNAs and three internal controls showed high potential for CRC detection (AUC = 0.948).
- OAA1-based method could serve as a liquid biopsy tool for early CRC surveillance.

## Abstract

Lectin (OAA), isolated from the filamentous cyanobacterium Oscillatoria agardhii, exhibits high specificity and strong binding affinity for high-mannose (HM) N-glycans. Previous studies have demonstrated that OAA captured extracellular vesicles (EVs) derived from cancer cell lines. This study aimed to confirm the effectiveness of OAA in capturing HM N-glycans in blood and explore its potential in capturing circulating EVs derived from early-stage colorectal cancer (CRC) tumors.

OAA1 (a recombinant OAA variant) was used to capture HM N-glycans from blood samples. The ability of OAA1 to capture circulating EVs in patients with stage I CRC was assessed. The miRNA profiles of the OAA1-captured EVs were analyzed and compared between 60 patients with stage I CRC and 60 healthy controls. Statistical analyses were performed to evaluate the potential of the specific miRNAs as CRC biomarkers.

OAA1 effectively captured HM N-glycans in the plasma. Nanoparticle and immunoblot analyses confirmed the presence of EVs in the OAA1-captured from plasma. The miRNA profile of OAA1-captured EVs exhibited characteristics of patients with CRC. Statistical analysis identified five miRNAs (miR-122-5p, miR-130a-3p, miR-146a-5p, miR-15b-5p, and miR-126) and three internal control miRNAs (miR-93-5p, miR-192-5p, and miR-502-5p) with a high potential for cancer separation (area under the curve (AUC) = 0.948; sensitivity = 0.883; specificity = 0.933).

These results suggest that circulating miRNAs in OAA1-captured EVs could serve as biomarkers for the surveillance of early stage CRC using liquid biopsy. The OAA1-immobilized column device facilitates easier and quicker inspection processes and accentuates differences in circulating miRNAs associated with the disease.

OAA1-column showed potential clinical application to analyze circulating EVs and miRNAs associated with CRC, serving as a relevant liquid biopsy for early cancer detection.

## Linked entities

- **Proteins:** oaa1 (acylpyruvase Oaa1)
- **Diseases:** colorectal cancer (MONDO:0005575), CRC (MONDO:0005575)

## Full-text entities

- **Genes:** MIR1303 (microRNA 1303) [NCBI Gene 100302284] {aka MIRN1303, hsa-mir-1303}, MIR1225 (microRNA 1225) [NCBI Gene 100188847] {aka MIRN1225}, APOB (apolipoprotein B) [NCBI Gene 338] {aka FCHL2, FLDB, LDLCQ4, apoB-100, apoB-48}, TG (thyroglobulin) [NCBI Gene 7038] {aka AITD3, TGN}, CD81 (CD81 molecule) [NCBI Gene 975] {aka CVID6, S5.7, TAPA1, TSPAN28}, MIR147B (microRNA 147b) [NCBI Gene 100126311] {aka MIRN147B, mir-147b}, MIR935 (microRNA 935) [NCBI Gene 100126325] {aka MIRN935, hsa-mir-935, mir-935}, MIR215 (microRNA 215) [NCBI Gene 406997] {aka MIRN215, miRNA215, mir-215}, ALB (albumin) [NCBI Gene 213] {aka FDAHT, HSA, PRO0883, PRO0903, PRO1341}, CD9 (CD9 molecule) [NCBI Gene 928] {aka BTCC-1, DRAP-27, MIC3, MRP-1, TSPAN-29, TSPAN29}, MIR126 (microRNA 126) [NCBI Gene 406913] {aka MIRN126, miRNA126, mir-126}
- **Diseases:** Alzheimer's disease (MESH:D000544), ovarian, breast, and prostate cancer (MESH:D010051), CRC (MESH:D015179), I (MESH:D006969), Cancer (MESH:D009369), dementia (MESH:D003704), infectious diseases (MESH:D003141), neoplastic diseases (MESH:D004194), stage II- (MESH:D062706), hematologic malignancies (MESH:D019337), neurodegenerative diseases (MESH:D019636)
- **Chemicals:** Ni (MESH:D009532), PBS (MESH:D007854), CBB (MESH:C004692), 10xPBS (-), GSH (MESH:D005978), acetic acid (MESH:D019342), TBS-T (MESH:C027647), mannose (MESH:D008358), His (MESH:D006639), bromophenol blue (MESH:D001978), OAA (MESH:D062907), glycan (MESH:D011134), silica (MESH:D012822), imidazole (MESH:C029899), SDS (MESH:D012967), Alexa Fluor 488 C5 Maleimide (MESH:C504424), Cellulose acetate (MESH:C005062), sodium citrate (MESH:D000077559), EDTA (MESH:D004492), NTA (MESH:D009571), 2-mercaptoethanol (MESH:D008623), NaCl (MESH:D012965), Sodium (MESH:D012964), sulfate (MESH:D013431), glycerol (MESH:D005990), Tween 20 (MESH:D011136), N (MESH:D009584)
- **Species:** Sus scrofa (pig, species) [taxon 9823], Homo sapiens (human, species) [taxon 9606], Mus musculus (house mouse, species) [taxon 10090], Planktothrix agardhii (species) [taxon 1160]

## Figures

5 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12343284/full.md

---
Source: https://tomesphere.com/paper/PMC12343284